PT-141 (Bremelanotide): Melanocortin Receptor Research

What Is PT-141?

PT-141, also known as Bremelanotide, is a cyclic heptapeptide that acts as a non-selective agonist at melanocortin receptors, with particular affinity for the MC3R and MC4R subtypes. It was originally developed as a metabolite of Melanotan II, a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH).

The melanocortin system is one of the most phylogenetically conserved signaling networks in vertebrate biology, regulating processes including pigmentation, energy homeostasis, cardiovascular function, inflammation, and sexual function. PT-141 has become an important research tool for studying central melanocortin receptor signaling pathways.

The Melanocortin Receptor Family

There are five melanocortin receptor subtypes (MC1R through MC5R), each with distinct tissue distribution and physiological roles:

MC1R is primarily expressed in melanocytes and modulates pigmentation. MC2R is the ACTH receptor in the adrenal cortex. MC3R is expressed in the hypothalamus and peripheral tissues, involved in energy homeostasis. MC4R is expressed centrally in the hypothalamus, paraventricular nucleus, and other brain regions, regulating appetite, energy expenditure, and autonomic function. MC5R is involved in exocrine gland function.

PT-141 interacts primarily with MC3R and MC4R, making it a valuable research tool for studying central nervous system melanocortin signaling.

Mechanism of Action

Central MC4R Activation

Research has established that PT-141's primary mechanism involves agonism at MC4R receptors in the central nervous system. Unlike compounds that act on peripheral vascular targets, PT-141's effects are mediated through hypothalamic and brainstem pathways. Studies published in the Journal of Pharmacology and Experimental Therapeutics have documented its selective central nervous system activity.

Downstream Signaling

MC4R activation by PT-141 triggers intracellular cAMP (cyclic adenosine monophosphate) production via Gs-protein coupling. This initiates a signaling cascade that influences neural circuits involved in autonomic regulation, energy balance, and behavioral responses. The specificity of this pathway makes PT-141 useful for dissecting melanocortin receptor biology in controlled research settings.

Research History and Development

PT-141's research trajectory is notable for its progression from pigmentation research to melanocortin signaling studies. Initial investigations into Melanotan II (an alpha-MSH analog developed at the University of Arizona) revealed unexpected central nervous system effects beyond pigmentation. PT-141 was subsequently identified as the active metabolite responsible for the central melanocortin activity.

The synthetic form (bremelanotide) was later studied in Phase 3 clinical trials, providing substantial pharmacological and safety data. This clinical-grade research background makes PT-141 one of the most well-characterized melanocortin agonists available to the research community.

Structural Properties

PT-141 has the molecular formula C₅₀H₆₈N₁₄O₁₀ with a molecular weight of approximately 1,025 Daltons. It is a cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The cyclic structure enhances metabolic stability compared to linear analogs, and the inclusion of D-Phe (a non-natural amino acid) further increases resistance to enzymatic degradation.

Key Distinctions in Research

PT-141 is distinct from PDE5 inhibitors (such as sildenafil) in that it acts through central melanocortin pathways rather than peripheral vascular mechanisms. This fundamental mechanistic difference makes it a unique research tool for studying central nervous system regulation of autonomic responses. Research design should account for this central mechanism when planning experiments.

Research Considerations

Studies involving PT-141 should consider its receptor selectivity profile (non-selective across MC1R-MC5R, with highest affinity for MC3R and MC4R), its central site of action (requiring appropriate delivery to reach CNS targets in in vivo models), and its cyclic stability (which affects pharmacokinetic parameters in research protocols).

PT-141 is sold as a research peptide only. Not for human consumption.

Frequently Asked Questions

What receptors does PT-141 target?

PT-141 is a non-selective melanocortin receptor agonist with highest affinity for MC3R and MC4R. These receptors are primarily expressed in the central nervous system, particularly the hypothalamus and brainstem, where they regulate energy homeostasis and autonomic function.

How is PT-141 different from Melanotan II?

PT-141 is a metabolite of Melanotan II. While Melanotan II activates all five melanocortin receptor subtypes (including MC1R, which drives pigmentation), PT-141 has reduced MC1R affinity and acts primarily through central MC3R and MC4R pathways. PT-141 is also a cyclic heptapeptide versus Melanotan II's cyclic heptapeptide with a linear extension.

Is PT-141 the same as bremelanotide?

Yes. PT-141 and bremelanotide refer to the same compound — a cyclic heptapeptide melanocortin receptor agonist. PT-141 is the research designation, while bremelanotide is the International Nonproprietary Name (INN) used in clinical and pharmaceutical contexts.